Education
About Us
Working with TipRanks
Follow Us
HTEC - ETF AI Analysis
Top Page
ROBO Global Healthcare Technology and Innovation ETF (HTEC)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid gains this year, indicating strong overall momentum.
Focused Healthcare Exposure
With over 92% of assets in healthcare, the fund targets a high-growth sector with innovation potential.
Global Diversification
While heavily U.S.-focused, the ETF includes holdings from several international markets, adding some geographic balance.
Negative Factors
High Expense Ratio
The ETF charges a relatively high fee compared to many other funds, which can eat into returns over time.
Underperforming Holdings
Some top positions, like Danaher and Thermo Fisher, have shown weak year-to-date performance, which could drag on overall returns.
Sector Concentration Risk
The fund's heavy focus on healthcare makes it vulnerable to downturns or regulatory changes in this single sector.
HTEC vs. SPDR S&P 500 ETF (SPY)
AUM53.93M
RegionGlobal
Expense Ratio0.68%
Beta0.93
IssuerROBO Global
Inception DateJun 25, 2019
Dividend YieldN/A
Asset ClassEquity
Index TrackedROBO Global Healthcare Technology and Innovation ETF
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume11,032
30 Day Avg. Volume7,352
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
40.76Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering63
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HTEC Summary
The ROBO Global Healthcare Technology and Innovation ETF (HTEC) is an investment fund focused on companies using advanced technology to improve healthcare. It includes innovative firms working on medical robotics, telehealth, genomic sequencing, and artificial intelligence in medicine. Some well-known companies in the ETF are Thermo Fisher and Vertex Pharmaceuticals. This ETF might appeal to investors looking for growth opportunities in the rapidly evolving healthcare technology sector. However, new investors should be aware that the fund’s performance is tied to the healthcare industry, which can be affected by regulatory changes and market shifts.
How much will it cost me?The ROBO Global Healthcare Technology and Innovation ETF (HTEC) has an expense ratio of 0.68%, which means you’ll pay $6.80 per year for every $1,000 invested. This is higher than average because it is actively managed and focuses on a specialized niche in healthcare technology, requiring more research and expertise. It offers exposure to innovative companies in areas like medical robotics and genomic sequencing.
What would affect this ETF?HTEC could benefit from growing demand for healthcare innovation, driven by advancements in medical robotics, telehealth, and AI applications, as well as increased global focus on improving healthcare efficiency and outcomes. However, the ETF may face challenges from regulatory changes in healthcare technology, potential economic slowdowns impacting funding for innovation, or competition within the sector. Its global exposure and focus on cutting-edge companies position it well for long-term growth, but risks remain tied to sector-specific volatility.
HTEC Top 10 Holdings
HTEC is laser-focused on healthcare innovation, with a global portfolio dominated by cutting-edge companies in medical robotics, genomics, and AI-driven diagnostics. GRAIL Inc. is rising steadily, benefiting from strong revenue growth and partnerships, while Guardant Health and Exact Sciences are showing mixed signals—strong technical momentum but weighed down by profitability concerns. Regeneron and Intuitive Surgical, steady performers, add stability to the fund, though valuation challenges linger. With its heavy concentration in healthcare technology, HTEC is a bet on the future of medicine, but some holdings face hurdles that could temper near-term gains.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 3.68% | $1.98M | $8.78B | 173.87% | 57 Neutral | |
| AxoGen | 3.03% | $1.63M | $1.52B | 120.36% | 63 Neutral | |
| Guardant Health | 3.01% | $1.62M | $14.04B | 192.43% | 58 Neutral | |
| GRAIL Inc | 3.00% | $1.62M | $4.08B | 384.30% | 70 Outperform | |
| Exact Sciences | 2.77% | $1.49M | $19.19B | 61.52% | 62 Neutral | |
| Natera | 2.43% | $1.31M | $33.41B | 43.21% | 68 Neutral | |
| Intuitive Surgical | 2.09% | $1.13M | $201.58B | 3.83% | 78 Outperform | |
| Illumina | 2.04% | $1.10M | $19.56B | -8.49% | 73 Outperform | |
| Thermo Fisher | 2.02% | $1.09M | $216.12B | 10.44% | 73 Outperform | |
| Adaptive Biotechnologies | 2.01% | $1.08M | $2.67B | 178.47% | 53 Neutral |
HTEC Technical Analysis
Positive
―
Price Trends
33.21
Positive
31.49
Positive
29.51
Positive
Market Momentum
0.87
Negative
64.65
Neutral
78.28
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HTEC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 34.62, equal to the 50-day MA of 33.21, and equal to the 200-day MA of 29.51, indicating a bullish trend. The MACD of 0.87 indicates Negative momentum. The RSI at 64.65 is Neutral, neither overbought nor oversold. The STOCH value of 78.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HTEC.
HTEC Peer Comparison
Comparison Results
Performance Comparison
HTEC
ROBO Global Healthcare Technology and Innovation ETF
36.10
5.78
19.06%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
HEAL
Global X HealthTech ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
LGHT
Langar Global HealthTech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents